In rats, tirzepatide cut cocaine-seeking across every measure researchers tried
The same drug sold as Zepbound and Mounjaro reduced cocaine-evoked dopamine release and blocked drug-associated place preference in rodents. It's animal data, not a human addiction treatment.
Cocaine use disorder has no FDA-approved pharmacological treatment, and relapse rates remain high even after extended abstinence. A study published this week in eBioMedicine tested whether tirzepatide — the dual GIP/GLP-1 receptor agonist sold as Zepbound and Mounjaro for obesity and diabetes — could alter cocaine-related behavior in male rodents, and found effects across nearly every measure the researchers tried [s1].
Why researchers are looking at GLP-1 drugs for addiction
People taking GLP-1 receptor agonists for obesity or diabetes have anecdotally reported reduced urges to drink alcohol or use other addictive substances, a pattern that has prompted a wave of research into GLP-1 drugs and addiction, including a separate large cohort study of veterans published in The BMJ earlier this month linking GLP-1 use to lower rates of several substance use disorders [s1]. The mechanism researchers propose: GLP-1 receptors are present in brain regions that regulate motivation to seek both food and addictive drugs — the hippocampus, amygdala, ventral tegmental area, and nucleus accumbens among them — suggesting a single receptor pathway might influence both behaviors [s1].
What this study tested
Researchers examined whether tirzepatide alters cocaine-related behavioral and neurochemical responses in male rodents [s1]. Cocaine self-administration was reduced by tirzepatide in a dose-dependent manner (p < 0.001) [s1]. The drug also diminished cocaine-evoked dopamine responses across several measures: attenuated locomotor stimulation (p < 0.001), reduced conditioned place preference — a standard measure of drug reward, in which animals normally seek out an environment previously paired with a drug (p < 0.001) — and lower dopamine levels in the nucleus accumbens, a core reward-circuit structure, across two different cocaine doses (p < 0.01) [s1].
Beyond the reward measures, tirzepatide reduced the motivation to self-administer cocaine even when the effort required to obtain it was increased (p < 0.05), and it blunted reinstatement of cocaine-seeking behavior in a model of relapse (p < 0.001) [s1]. It also prevented the expression of cocaine-induced locomotor sensitization — the progressive intensification of cocaine's stimulant effects with repeated use — suggesting effects beyond the acute reward response [s1]. Neurochemical analysis found tirzepatide normalized cocaine-induced dopamine elevations in mesocorticolimbic brain circuits and the lateral septum (both p < 0.001), alongside changes in GABA and glutamate signaling in the same regions (both p < 0.01) [s1].
Reading the result
Every measure in this study pointed the same direction, across self-administration, effort-based motivation, relapse, reward learning, and sensitization — a consistency the study's design specifically aimed to establish by testing multiple, complementary behavioral paradigms rather than a single outcome [s1]. That breadth is what distinguishes it from a single positive finding: it's harder to dismiss a drug effect as a fluke of one specific test when the same direction shows up across five or six different measures tied to different aspects of addiction.
That said, this is animal research — specifically, male rodents — and translating rodent self-administration and relapse models to human cocaine use disorder is not guaranteed, particularly given how many promising rodent-model addiction treatments have failed to replicate in human trials historically. The study did not include female animals, so whether the effect holds across sex is untested here. And rodent "relapse" and "motivation" paradigms, while standardized and widely used in addiction neuroscience, are models of specific human phenomena rather than the phenomena themselves.
What the researchers say it means
The study's authors frame their interpretation cautiously: given tirzepatide's existing clinical availability for obesity and diabetes, the findings suggest the drug "merits investigation as a potential treatment approach" for cocaine use disorder [s1] — language pointing toward future human trials rather than an established treatment.
What to watch
Whether human trials of GLP-1 or dual GIP/GLP-1 drugs specifically for cocaine use disorder are launched, and whether the effect replicates in female animals. Tirzepatide is not approved for cocaine use disorder or any addiction indication; this article describes preclinical animal research and is not medical advice.
Sources
Sources
More on
Semaglutide and tirzepatide cut alcohol-related hospitalizations by up to 65%
Four separate trial emulations, each with a different comparator, all pointed the same direction. The strongest effect appeared among people being treated for alcohol use disorder.
From rodent cages to Medicare claims: GLP-1 drugs and opioid use disorder
A review lays out the evidence chain: animal studies showing reduced drug-seeking, one small human trial, and record-based analyses linking GLP-1 prescriptions to 40% fewer opioid overdoses.
In 40 people with cocaine use disorder, psilocybin nearly doubled abstinence odds
No medication has proven effective for cocaine use disorder. A single psilocybin dose, paired with therapy, produced more abstinent days and a longer time to relapse than an active placebo.
Eighteen months, 14 new trials: the obesity-drug evidence base has doubled in size
An updated Annals review now covers 38 randomised trials and 25,816 people. Tirzepatide leads the marketed drugs at 19.0% placebo-subtracted weight loss; the experimental multiagonists run higher.